Dose Escalation Study of Intravenous Baclofen in Healthy Adult Volunteers

Completed · Phase 1

Conditions studied: Safety and Pharmacokinetics of Intravenous Baclofen

In brief

The objective of this study is to determine safety and characterize pharmacokinetics of higher doses of intravenous baclofen in healthy subjects. Thirty-six healthy adults received a single dose of PO baclofen (10mg, 15mg or 20mg) and a 10-minute infusion of IV baclofen (7.5mg, 11.5mg or 15mg respectively) with a minimum 48-hour wash out period. Twelve subjects also received a 60-minute infusion of 15mg IV baclofen following an additional 48-hour wash out period. The pharmacokinetic and tolerability information gained from this study will support the development of further studies to assess the use of IV baclofen to prevent or treat baclofen withdrawal syndrome.

Key facts

Study ID

NCT01931319

Run by

University of Minnesota

People needed

39

Starts

2014-01-01

Expected to finish

2014-06-01

Last updated by the study team

2019-05-07

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Males and females between the ages of 18-65.
• Subjects are capable of giving informed consent.
• Female subjects must be post-menopausal for at least 1 year, or surgically incapable of bearing children, or practicing at least one or more of the following methods of contraception for three months prior to, and during the study: hormonal, intrauterine device (IUD), or barrier method in combination with a spermicide.
• Subject should be medication free, other than hormonal birth control, for 48 hours before through 24 hours after study drug administration. If the need for medication is identified during this time period, it will be discussed with and approved by the PI.

You may not qualify if…

• Women who are pregnant.
• Women who are breastfeeding.
• Subject has a history of intolerance to IV administration of medication.
• Subject has a known hypersensitivity to baclofen.
• Subject has a significant history of cardiac, neurologic, psychiatric, oncologic, endocrine, metabolic, renal or hepatic disease
• Subject has taken or used any investigational drug or device in the 30 days prior to screening.
• Subject has taken either prescribed or over the counter medication for 48 hours prior to baclofen administration on either of the study days, other than hormonal birth control.
• Subject reveals clinically significant abnormalities on screening laboratory tests.
• Subject is a non-English speaker, such that ability to ascertain neurological status would require an interpreter.
• Sleep deprivation (for example. working the night shift the evening prior to the study).

Where it is running

• University of Minnesota — Minneapolis, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.